OUTLOOK THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.79 USD | +3.45% |
|
+1.22% | -0.06% |
| May. 21 | CoStar Group has room for expansion |  |
| May. 16 | Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024 |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 9.57M | Capitalization | 176M |
|---|---|---|---|---|---|
| Net income 2024 * | -121M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 18.4 x |
| P/E ratio 2024 * |
-1.34
x | P/E ratio 2025 * |
-3.38
x | Employees | 24 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Outlook Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -5.88% | ||
| 1 week | +2.73% | ||
| Current month | -15.58% | ||
| 1 month | -8.17% | ||
| 3 months | -14.16% | ||
| 6 months | -16.44% | ||
| Current year | -4.44% |
1 week
7.34
8.30
1 month
6.809.29
Current year
5.0412.85
1 year
4.0040.60
3 years
4.0065.40
5 years
4.0085.20
10 years
4.00878.40
| Managers | Title | Age | Since |
|---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +9.29% | - | |
| 0.00% | 17 M€ | +4.66% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 7.87 | +4.52% | 149 895 |
| 24-05-23 | 7.53 | -5.87% | 247,818 |
| 24-05-22 | 8 | +1.65% | 319,959 |
| 24-05-21 | 7.87 | -1.01% | 192,096 |
| 24-05-20 | 7.95 | +2.19% | 236,478 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Calendar
2024-08-13
- Q3 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.53
USD
Average target price
38.43
USD
Spread / Average Target
+410.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.44% | 176M | |
| +64.92% | 62.86B | |
| -1.85% | 41.38B | |
| +44.76% | 40.38B | |
| -8.93% | 27.64B | |
| +13.05% | 26.46B | |
| -21.96% | 18.9B | |
| +4.21% | 12.67B | |
| +25.74% | 12.27B | |
| +27.42% | 12.07B |
- Stock Market
- Equities
- OTLK Stock
